Wacker Biotech, Eclipsebio form strategic collaboration on RNA therapeutics development, manufacturing

• Wacker Chemie’s Wacker Biotech entered a strategic collaboration with Eclipsebio to expand end-to-end RNA therapeutics development through GMP manufacturing.
• Eclipsebio will provide AI-driven RNA design, optimization, sequencing-based characterization to improve manufacturability, yield, stability, purity, protein expression.
• Wacker Biotech will supply GMP-compliant plasmid DNA, RNA, lipid nanoparticles, supporting scale-up from in vitro transcription to encapsulation for clinical use.
• Partnership targets RNA developers needing early candidate design through clinic-ready production, strengthening Wacker Biotech’s contract research services offering.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wacker Chemie AG published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.